London Hospitals Launch Trial of Drug that Could Reduce Coronavirus Risk in Diabetics - COVID-19 Clinical Trial
Breaking News | COVID-19

London Hospitals Launch Trial of Drug that Could Reduce Coronavirus Risk in Diabetics

Medics at the Royal London and Whipps Cross hospitals are leading a national trial that will offer people with type 1 or 2 diabetes who are admitted for treatment for covid an additional therapy.One in three deaths from covid in English hospitals have been associated with diabetes, as a result of such patients typically having problems with high blood sugar levels.

The drug, AZD1656, was originally developed by Astra Zeneca for another use and has been used to treat kidney transplant patients. But it has not become a standard treatment for the control of blood sugars as its benefits tend to wear off after several months.

Relief Therapeutics Seeks U.S. Emergency Approval for Drug Against COVID-19

Relief Therapeutics said on Wednesday it and U.S. partner NeuroRx asked the U.S. Food and Drug Administration for emergency approval for a drug it aims to repurpose against COVID-19, citing a 51-person study the Swiss drugmaker said showed the medicine helped sick patients.

“Patients treated with RLF-100 demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement,” the company said in a statement, adding the request, if granted, would make the drug — previously used against conditions including erectile dysfunction — available to those in intensive care who have exhausted all approved treatments.

Share this:

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.